Juan C Sarmiento-Monroy, MD, MSc
Juan C. is a Rheumatologist and clinical research fellow at the Hospital Clinic of Barcelona. His main research interests include the validation of biomarkers in RA-ILD and the development of digital tools for patients with SLE.
Juan C. is a member of the EMEUNET Education Sub-Committee.
| Poster 0206| Saturday 16th November 2024 10:30 Health Services Research – ACR/ARP Poster I Presenting author: MS Tang (Singapore) Title: Urate Lowering Therapy to Acute Treatment Ratio (ULTrA) Index – a Novel Quality Indicator Associated with Reduced Hospital Admissions for Gout  This retrospective study analyzed electronic health records of gout patients in Singapore from 2022-2023. It introduced the ULT to Acute Treatment ratio (ULTrA) as a quality index. Among 12,314 patients in 2022, only 46.1% received urate-lowering therapy, and 11.4% were hospitalized. The ULTrA index was inversely associated with hospitalization risk, suggesting its potential as a quality indicator for gout management and its ability to reduce hospital admissions. |
| Oral 0848| Saturday 16th November 2024 15:00 Abstracts: Epidemiology & Public Health I Presenting author: : G Challener (USA) Title: Impact of SGLT2i Initiation on the Need for Urate-Lowering Therapy and Colchicine Among Gout Patients with Type 2 Diabetes:Propensity-Score Matched, Active Comparator, New User Design Study This study found that SGLT2 inhibitors (SGLT2i) significantly reduced the need for urate-lowering therapy, colchicine prescriptions, and gout-related medical visits in type 2 diabetes patients compared to GLP1 receptor agonists. The results support SGLT2i use in gout patients with multiple comorbidities. |
| Poster 1088 | Sunday 17th November 2024 10:30 Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II Presenting author: C Rodríguez Alvear (Spain) Title: Prospective Evaluation of Carotid Atherosclerosis, Urate Deposits and Inflammation After One Year of Treatment in Newly Diagnosed Gout This 12-month study of 103 gout patients receiving urate-lowering therapy demonstrates that improvements in carotid atheroma plaques were significantly more prevalent in those with absent Power Doppler signals. These findings provide additional evidence supporting the link between crystal-induced inflammation and atherosclerosis in gout patients. |
| Poster 1992 | Monday 18th November 2024 10:30 Immunological Complications of Medical Therapy Poster Presenting author: A Herron (USA) Title: Gout Flares Following Immune Checkpoint Inhibitors Treatment This study investigated the impact of immune checkpoint inhibitors (ICIs) on gout flares among Veterans. Of 308 patients examined, 35 (11.3%) had pre-existing gout, with 17 (48.5%) experiencing flares within six months of initiating ICI treatment. Elevated serum urate levels and atezolizumab use emerged as potential risk factors. |
| Oral 2562 | Monday 18th November 2024 13:00 Abstracts: Metabolic & Crystal Arthropathies Presenting author: S Carrabin (France) Title: Efficacy and Safety of Tocilizumab in the Treatment of Chronic Inflammatory Forms of CPPD: Retrospective Study of 55 Cases This study evaluated tocilizumab (TCZ) for chronic inflammatory calcium pyrophosphate deposition disease (CPPD) in 55 patients. Over six months, pain scores significantly decreased from 60.8 to 37.4. Despite 40% discontinuing treatment due to inefficacy or intolerance, TCZ improved CPPD control in more than two-thirds of patients. |